11 Amendments of Edina TÓTH related to 2020/2071(INI)
Amendment 45 #
Motion for a resolution
Recital A a (new)
Recital A a (new)
Aa. whereas medicine shortages are a growing public health threat with a serious impact on health care systems and public health;
Amendment 91 #
Motion for a resolution
Recital C
Recital C
C. whereas the loss of European sovereignty and independence in the health sector is linked to the relocation of production, with 40% of medicinal end products marketed in the EU now originating in third countries; whereas the onlyone way to save money is to rely heavily on subcontractors to produce pharmaceutical raw materials in Asia, where labour costs and environmental standards are lower, with the result that 80% of active ingredients are manufactured outside the EU, mainly in China and India;
Amendment 96 #
Motion for a resolution
Recital C a (new)
Recital C a (new)
Ca. whereas, as the consequence of the COVID19 health crisis, the EU will be facing an economic crisis that will have impact on the shortages of medicines and the competitiveness of the EU pharmaceutical industry;
Amendment 105 #
Motion for a resolution
Recital C b (new)
Recital C b (new)
Cb. whereas, the EU has an important existing manufacturing footprint and it is important to secure it through sustainable economic, regulatory and industrial incentives;
Amendment 348 #
Motion for a resolution
Paragraph 6
Paragraph 6
6. Urges the Commission and the Member States to introduce tax and financial incentives in return for appropriate commitments and to authorise state aid to encourage producers to locate their operations in Europe, from compound manufacturing to packaging and distribution; and urges Member States to secure existing operations; emphasises the strategic significance of this sector and the importance of investing in European companies, in the interests of resource diversification;
Amendment 440 #
Motion for a resolution
Paragraph 9 a (new)
Paragraph 9 a (new)
9a. Calls on the Commission to take action against the spread of falsified medicines from unauthorised websites and vendors that are raising concerns nowadays; this practice can cause serious harm and can lead to severe health problems or worsen the health condition of citizens; EU coordination in mapping and combatting of counterfeit of medicines is essential;
Amendment 532 #
Motion for a resolution
Paragraph 13
Paragraph 13
13. Calls on the Commission to develop European health strategies on the basis of a common basket of drugs for the treatment of cancer and infections whose prices are harmonised, in a bid to counter recurrent shortages and ensure that patients have access to treatment;
Amendment 568 #
Motion for a resolution
Paragraph 15
Paragraph 15
15. Calls on the Commission and the Member States to adopt a joint definition of ‘medicines of strategic importance for health care’ and of ‘criticality’, emphasising the value of these medicines for public health, the lack of alternatives and the vulnerability of the production chain; calls for a European regulatory authority to be designated to carry out the task of setting quotas for the allocation of medicines from that reserve to the Member States;
Amendment 599 #
Motion for a resolution
Paragraph 16
Paragraph 16
16. Calls on the Commission and Member States to develop innovative and coordinated strategies and to step up exchanges of good practice in the area of stock managementto prevent shortages; considers that the European Medicines Agency (EMA) could be designated as the regulatory authority tasked with preventing shortages of essential medicines, with a correspondingly wider remit and more staff;
Amendment 632 #
Motion for a resolution
Paragraph 17 a (new)
Paragraph 17 a (new)
17a. Calls on the Commission to take appropriate action on parallel trade in favour to prevent and address medicine shortages;
Amendment 694 #
Motion for a resolution
Paragraph 20
Paragraph 20
20. Calls for an electronic product information notice to be drawn up in all the Union languages for every medicine on the EU market, in order to facilitate sales of medicines between Member States; recommends the provision of more comprehensive information on the origin of medicinleaflet in the languages for the countries where the medicine is marketed as supporting document in order to facilitate sales of medicines between Member States;